SCHEMBL2853460

SCHEMBL2853460

O=C(CCl)Nc1nc2ccc(Oc3cccc(NC(=O)c4cccc(C(F)(F)F)c4Cl)c3)nc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.47
FLT1 P17948 3/20 0.47
PDGFRB P09619 2/20 0.47
KIT P10721 2/20 0.47
BRAF P15056 5/20 0.46
MAP2K7 O14733 5/20 0.45
MAPK1 P28482 2/20 0.40
MITF O75030 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
FLT4 P35916 2/20 0.39
RET P07949 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNK3 O14649 1/20 0.38
KCNK9 Q9NPC2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851200 0.90 KDR (0.50) KDRFLT1PDGFRBKITBRAF
SCHEMBL2851230 0.88 KDR (0.61) KDRFLT1PDGFRBKITBRAF
SCHEMBL2855475 0.88 KDR (0.41) KDRFLT1PDGFRBKITBRAF
SCHEMBL2855619 0.87 KDR (0.48) KDRFLT1PDGFRBKITBRAF
SCHEMBL2853872 0.86 KDR (0.47) KDRFLT1PDGFRBKITBRAF
SCHEMBL2857661 0.84 KDR (0.51) KDRFLT1PDGFRBKITBRAF
SCHEMBL2853585 0.82 KDR (0.39) KDRFLT1PDGFRBKITBRAF
SCHEMBL2862228 0.79 KDR (0.47) KDRFLT1PDGFRBKITBRAF
SCHEMBL2857639 0.77 KDR (0.60) KDRFLT1PDGFRBKITBRAF
SCHEMBL2858590 0.77 ALDH1A1 (0.41) KDRFLT1PDGFRBKITBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 KDR 983/4885FLT1 1422/4885PDGFRB 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.